Zepbound

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access despite strong market demand. What Happened: The medications cost around $500 monthly for uninsured patients, while insured coverage remains inconsistent...

Eli Lilly & Co. (NYSE:LLY) may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down. Zepbound's Momentum Keeps Eli Lilly In The Lead With Zepbound continuing to dominate the GLP-1 obesity...

Weight-loss drugs are suppressing appetites for millions of Americans, threatening to upend dining habits at fast-food chains and casting a shadow over the restaurant industry’s long-term growth. The stark warning came from Redburn Atlantic, which on Tuesday issued a rare double downgrade on...

Eli Lilly and Company’s (NYSE:LLY) Zepbound demonstrated superior weight reduction compared to Novo Nordisk A/S’s (NYSE:NVO) Wegovy in a 72-week head-to-head trial. What Happened: Participants treated with tirzepatide (Zepbound) achieved an average weight loss of 20.2%, compared to 13.7...

Eli Lilly And Co (NYSE:LLY) is scheduled to report its quarterly results on Thursday. The company is likely to report its first-quarter results in line with peers, with some tariff and policy-related commentary during the earnings call, according to Goldman Sachs. The Eli Lilly Analyst: Analyst...

The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the healthcare supply chain. According to Gill, while Eli Lilly And Co's (NYSE:LLY) direct-to-consumer push is...

Weight loss drugs have taken the world by storm and saw strong demand for the companies selling them. A new study shows that despite the increase usage of weight loss drugs, obesity is still on the rise and could hit staggering numbers in the next 25 years. What Happened: The public support of...

On Friday, the U.S. Food and Drug Administration approved Eli Lilly and Co.’s (NYSE:LLY) weight loss drug Zepbound for treating sleep apnea What Happened: The FDA’s decision makes Zepbound the first approved drug treatment for patients with obesity and moderate-to-severe obstructive...

Novo Nordisk A/S (NYSE:NVO) saw its stock crater nearly 20% on Friday, eyeing its worst single-day drop since April 2002, after releasing underwhelming weight-loss trial results for its much-hyped obesity drug, CagriSema. To put the move in perspective, the only steeper plunge in the Danish pharma...

Eli Lilly and Co (NYSE:LLY) is making headlines with its $15 billion share buyback plan and a 15% dividend boost. Yet, as the Indianapolis-based pharma giant enjoys the success of blockbuster drugs like Mounjaro and Zepbound, its stock is sending mixed technical signals ahead of its next move. Eli...

The battle for the multibillion-dollar obesity market just got fiercer. Amgen Inc's (NASDAQ:AMGN) new drug candidate, MariTide, reported promising results, helping patients shed around 20% of their body weight. But when up against the current titans — Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/...

Eli Lilly and Co. (NYSE:LLY) has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over the last month. Chart created using Benzinga Pro Lilly stock is well below its summer highs and is trading at $746.94 at the time of writing. The once red-hot...

Eli Lilly & Co. (NYSE:LLY) shares have nosedived 12.5% month-to-date through Nov. 19, putting the stock on track for its worst monthly performance since February 2009, when it tumbled 20.2%. The pharmaceutical giant, which ranks 11th by market capitalization in the S&P 500 and holds the...

Eli Lilly And Co (NYSE:LLY) experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick occurs as the company gears up to announce its third-quarter earnings. Wall Street analysts are forecasting earnings per share of $1.45 and revenues of $12.1 billion. What...

Editor’s note: This story has been updated to clarify that Eli Lilly is set to report earnings premarket Wednesday. Eli Lilly and Co (NYSE:LLY) will be reporting its third-quarter earnings on Wednesday. Wall Street expects $1.45 in EPS and $12.1 billion in revenues when the company reports...